A Comprehensive Comparative Analysis of Dairy Protein Sources: Establishing the Functional and Tolerability Superiority of Cheese Whey Protein Concentrate (WPC 80) Over Milk Protein Concentrate (MPC)

Eugene Capitano, DC, MSc in Neuroscience & Psychology of Mental Health – King's College London

Introduction: The Evolving Debate in Dairy Protein Nutrition

Dairy proteins represent some of the most nutritionally complete and highly bioavailable sources of amino acids available, serving as fundamental substrates for muscle protein synthesis, metabolic health, and general well-being (Mehra et al., 2021; Pinckaers et al., 2022). The two primary commercial derivatives, Milk Protein Concentrate (MPC) and Whey Protein Concentrate (WPC), are often positioned as competitive or interchangeable supplements, yet their divergent manufacturing processes yield substantial differences in bioactive composition, digestion kinetics, and gastrointestinal tolerability (Mehra et al., 2021; Pinckaers et al., 2022). MPC is typically produced by ultrafiltration of skim milk, retaining the native 80:20 ratio of casein to whey, along with milk's indigenous sugar load (Mehra et al., 2021). In stark contrast, WPC 80 originates from the liquid whey byproduct of cheese production, a process that inherently separates a unique fraction of bioactive peptides and achieves a pronounced reduction in residual sugars during subsequent filtration (Rackerby et al., 2024; Evans et al., 2012).

There are subtle yet critical compositional differences inherent to cheese-derived WPC80 that render it the superior and more functionally relevant protein source for the overwhelming majority of the global population. This argument is predicated on three major pillars of scientific evidence:
(1) the vast reduction in fermentable carbohydrates (lactose and galactose) in WPC80, which directly addresses the global epidemic of lactase non-persistence and mitigates gastrointestinal distress while supporting gut barrier integrity;
(2) the presence of unique bioactive components, notably glycomacropeptide (GMP), which modulate

immune signaling and promote a healthy gut microbiome; and

(3) the rapid digestion kinetics and potent aminoacidemia of WPC80, which produce more effective metabolic signaling and support the mitigation of age-related anabolic resistance, critical for sarcopenia prevention and recovery from illness (Misselwitz et al., 2019; Rackerby et al., 2024; Connolly et al., 2023).

Analytical Framework for Comparing MPC and WPC80

This review evaluates MPC and cheese-derived WPC80 across four mechanistically grounded domains that determine their real-world impact on human tolerability, immunometabolic function, and metabolic health:

1. Gastrointestinal compatibility and fermentable carbohydrate burden
2. Bioactive peptide composition and immunometabolic effects
3. Digestion kinetics, aminoacidemia, and metabolic/anabolic signaling
4. Anabolic efficacy and the capacity to counteract age-related anabolic resistance
5. Rethinking “Naturalness”: MPC, WPC80, and Human Biology
6. The A1/A2 Casein Distinction: Implications for Dairy Protein Tolerance, Inflammation, and the Gut Microbiome

These domains collectively determine a protein’s suitability for global populations with varying degrees of lactase persistence, metabolic flexibility, insulin resistance, and risk of sarcopenia. The following sections examine each domain in detail.

I. **The Fundamental Distinction: Processing, Composition, and Gastrointestinal Tolerability**

The consumer choice between MPC and WPC 80 often comes down to an acute physiological reality: gastrointestinal tolerance. This factor is directly governed by the carbohydrate load retained during processing and is amplified by the global prevalence of lactase non-persistence (Misselwitz et al., 2019).

A. Manufacturing Pathways and Proteomic Differences

Milk protein, comprising roughly eighty percent slow-digesting casein and twenty percent fast-digesting whey, is a complex nutritional matrix (Mehra et al., 2021; Mitchell et al., 2015). MPC, manufactured directly from skim milk via membrane technologies, preserves this native casein:whey ratio and is often positioned as a complete, “milk-like” protein source (Mehra et al., 2021). Upon ingestion, the high casein fraction forms a firm clot in the stomach, resulting in slow, sustained digestion and a prolonged but attenuated appearance of amino acids in the circulation (Mitchell et al., 2015; Pinckaers et al., 2022).

By contrast, cheese-derived WPC80 is produced from the liquid whey fraction generated during casein coagulation in cheese making, a manufacturing pathway that is fundamentally distinct from concentrating whole milk. This route yields inherent compositional differences, most notably the presence of glycomacropeptide (GMP) and a higher proportion of non-protein nitrogen (NPN) species in WPC, components that are largely absent when proteins are isolated directly from skim milk (often termed serum protein concentrate, SPC), owing to the different separation and filtration points (Barbano et al., 2010). During cheese manufacture, enzymatic cleavage of κ-casein by rennet releases GMP into the whey stream (Rackerby et al., 2024; Adler et al., 2023). Subsequent ultrafiltration steps concentrate the whey proteins to ~80% while substantially removing residual carbohydrate and mineral fractions (Mehra et al., 2021). The resulting WPC80 therefore comprises rapidly absorbed, highly insulinotropic whey proteins together with unique bioactives such as GMP, distinguishing it both from the original milk substrate and from its MPC analogue (Mehra et al., 2021; Rackerby et al., 2024).

B. The Global Burden of Lactose and Galactose Malabsorption

The ability to maintain lactase enzyme activity into adulthood, known as lactase persistence (LP), is a relatively recent evolutionary trait, common predominantly in Northern European and some specific African and Middle Eastern pastoralist populations (Misselwitz et al., 2019; Anguita-Ruiz, Aguilera, & Gil, 2020; Gerbault et al., 2011). The ancestral, and globally predominant, condition is Lactase Non-Persistence (LNP), estimated to affect nearly seventy percent of the global population (Misselwitz et al., 2019; Fung, Xue, & Szilagyi, 2020).

MPC, by retaining the liquid milk matrix composition, contains significantly higher amounts of lactose than WPC 80, placing MPC consumption in direct conflict with the digestive physiology of the majority of the world (Mehra et al., 2021). Furthermore, lactose is a disaccharide composed of one molecule each of glucose and galactose (Mehra et al., 2021). In individuals with lactase non-persistence (LNP), undigested lactose and its galactose moiety reach the colon, where they undergo microbial fermentation, producing hydrogen, methane, short-chain fatty acids, and gas-related symptoms (Misselwitz et al., 2019).

C. Mechanisms of Sugar-Induced Gastrointestinal Distress and Barrier Dysfunction

A central mechanism linking the high lactose and galactose content of MPC to gastrointestinal and systemic dysfunction is the fate of unabsorbed, fermentable carbohydrates in lactase-non-persistent (LNP) individuals. Under normal physiology, lactose is hydrolyzed in the small intestine by the brush-border enzyme lactase, yielding glucose and galactose for immediate absorption. However, in the ~70% of the world population with reduced lactase expression after childhood, lactose remains intact and unabsorbed, passing into the colon as a disaccharide (Misselwitz et al., 2019). In this setting, lactose becomes a highly fermentable substrate for the colonic microbiota, undergoing rapid bacterial metabolism that generates large quantities of hydrogen, methane, carbon dioxide, and acidic metabolites such as lactate (Misselwitz et al., 2019; Oliveira et al., 2022). These fermentation products do not physically “attach” to colonocytes; rather, they create a biochemical and mechanical environment that stresses the intestinal epithelium, increasing luminal osmotic pressure, lowering pH, and driving distention, all of which contribute to abdominal pain, bloating, diarrhea, and visceral hypersensitivity in susceptible individuals (Misselwitz et al., 2019; Oliveira et al., 2022).

Crucially, this high-fermentation milieu also promotes disruption of tight junction integrity and enhances paracellular permeability. Acidic fermentation products, microbial shifts toward gas- and lactate-producing species, and mechanical distention collectively stimulate pro-inflammatory cytokines (e.g., TNF-α) and zonulin release, the latter being a key physiological regulator that actively loosens tight junctions (Li et al., 2016; Ioannou et al., 2025). As permeability increases, luminal components such as lipopolysaccharide (LPS), bacterial DNA, and peptidoglycans translocate across the epithelium, elevating systemic biomarkers including LBP and sCD14 and driving the low-grade endotoxemia implicated in metabolic syndrome and insulin resistance (Rohr et al., 2020; Zak-Gołąb et al., 2013). Thus, the high lactose burden in MPC is not merely a tolerability issue but represents a direct mechanistic pathway linking dairy carbohydrate malabsorption to intestinal barrier impairment and systemic inflammation. In contrast, the substantial reduction of fermentable carbohydrates in WPC80, achieved through cheese-derived processing—removes this entire pathological cascade for the majority of the global population.

II. Bioactive Superiority: Glycomacropeptide (GMP) and Immunomodulation

The unique molecular components present in WPC derived from the cheesemaking process, particularly GMP, endow it with functional properties that MPC cannot replicate (Mehra et al., 2021; Rackerby et al., 2024). The distinctive functional properties of WPC derived from cheesemaking, particularly those attributed to GMP, give it a "bioactive superiority" that whole MPCs or milk serum protein concentrates (SPCs) cannot replicate (Evans et al., 2010).

A. GMP: A Unique Cheese Whey Component and Potent Prebiotic

GMP is an O-glycosylated, hydrophilic peptide generated during cheese production through the rennet-mediated cleavage of κ-casein, and comprises roughly twenty percent of the mass of commercial WPC products (Rackerby et al., 2024; Mehra et al., 2021). Its structure includes covalently attached glycans—complex carbohydrate chains such as sialic acid, N-acetylgalactosamine, and galactose.

These glycans should not be confused with glyphosate or other agricultural chemicals; they are naturally occurring sugar moieties that are also found in human milk oligosaccharides. Because these glycans resist digestion in the upper gastrointestinal tract, GMP reaches the colon intact, where it directly interacts with the gut microbiota (González-Morelo & Garrido, 2024).

This digestion resistance positions GMP as a potent prebiotic. Prebiotics are substrates selectively utilized by host microorganisms that confer health benefits (Oliveira et al., 2022). GMP, both in intact form and after partial hydrolysis, exhibits strong bifidogenic activity, consistently promoting the growth of beneficial Bifidobacterium and Lactobacillus species across in vitro models, fecal batch cultures, and animal studies (Rackerby et al., 2024). This microbial shift enhances gut barrier integrity, immune modulation, and short-chain fatty acid (SCFA) production, all of which support gastrointestinal and systemic health (Rackerby et al., 2024; Gallo et al., 2024).

B. Modulating the Gut Microbiota: Bifidogenic Effects and Cross-Feeding

The prebiotic action of GMP reflects a sophisticated set of ecological interactions within the gut microbiome (González-Morelo & Garrido, 2024). Multiple studies demonstrate that strains such as *Bifidobacterium bifidum* and *Bifidobacterium infantis* exhibit robust growth when GMP is provided as the sole carbon source, underscoring its selective fermentability by beneficial taxa (González-Morelo & Garrido, 2024). Mechanistically, this process begins with the enzymatic liberation of glycan-derived fragments, most notably galacto-N-biose (GNB) and sialic acid, from the peptide backbone. These liberated glycans are then imported into bifidobacteria through specialized carbohydrate transport systems and metabolized through dedicated intracellular pathways (González-Morelo & Garrido, 2024).

Beyond direct utilization, GMP also fosters beneficial cross-feeding dynamics that enhance microbial diversity and ecosystem resilience. As primary degraders metabolize GMP, they release intermediary metabolites, including galactose, N-acetylgalactosamine, and sialic acid—into the surrounding milieu (González-Morelo & Garrido, 2024). These by-products serve as substrates for secondary microbial species that cannot utilize intact GMP, thereby expanding the trophic web and supporting a more complex, interdependent community structure. This targeted, glycan-driven mechanism of microbial enrichment operates independently of the bulk fermentable carbohydrate load characteristic of lactose-rich milk proteins, providing a microbiome-supportive effect without the gastrointestinal drawbacks associated with high lactose intake (González-Morelo & Garrido, 2024).

C. Anti-inflammatory Mechanisms: Cytokine Suppression and Barrier Integrity

The immunomodulatory capacity of WPC and GMP is a substantial argument for its use in combating the chronic, low-grade inflammation prevalent in obesity and metabolic syndrome (Olsen et al., 2023; Adler et al., 2023). Undigested, intact GMP can reduce the expression of pro-inflammatory mediators such as IL-1β and TNF-α in various cell models (Olsen et al., 2023; Adler et al., 2023). Mechanistically, GMP has been shown to inhibit key inflammatory cascades, including the NF-κB and MAPK signaling pathways, thereby interfering with the core cellular mechanisms that produce inflammatory cytokines (Adler et al., 2023).

Crucially, the products of *in vivo* human digestion of whey proteins—such as those present in cheese-derived WPC80, demonstrate the most potent anti-inflammatory effects among all dairy-derived substrates tested (Olsen et al., 2023). In controlled human digestion models, intestinally digested whey protein isolate (a purified whey fraction containing GMP and hydrolyzed whey peptides) produced the strongest suppression of tumor necrosis factor-α (TNF-α), a central cytokine mediating chronic mucosal and systemic inflammation (Lima et al., 2019; Olsen et al., 2023). These findings highlight that the unique peptide profile generated from whey protein digestion, including GMP-derived bioactives, is both highly bioavailable and functionally effective in down-regulating inflammatory signaling within the gut epithelium. The dual capacity of WPC80 to support beneficial microbial growth while simultaneously attenuating pro-inflammatory pathways positions it as a superior tool for protecting and restoring gut barrier integrity, effects not observed to the same extent with MPC's casein-dominant and lactose-rich matrix (Rackerby et al., 2024; Olsen et al., 2023).

III. Metabolic Regulation and Mitigating Type 2 Diabetes Risk

WPC80 exhibits distinct metabolic advantages over MPC, particularly in the regulation of postprandial glucose homeostasis and insulin dynamics, two central determinants in the prevention and management of type 2 diabetes mellitus (Connolly et al., 2023; Bell et al., 2025). These benefits arise from WPC80's rapid digestibility, superior amino acid kinetics, and its ability to restore physiological insulin responses that are characteristically impaired in insulin-resistant individuals. WPC80's metabolic superiority derives from both its biochemical profile and its ability to restore physiological responses often impaired in insulin resistance.

A. Amino Acid Kinetics and Insulinotropic Effects

WPC80 is exceptionally rich in branched-chain amino acids (BCAAs), most notably leucine, which serves as a potent metabolic signal regulating muscle anabolism and glucose metabolism (Bell et al., 2025). Owing to its rapid gastric emptying and proteolysis, WPC80 generates a markedly faster and higher rise in circulating amino acids, particularly leucine, than the slow, blunted aminoacidemia elicited by MPC's casein-dominant protein matrix (Hamarsland et al., 2019; Mitchell et al., 2015). This acute increase in plasma leucine is strongly insulinotropic, stimulating pancreatic β-cells, amplifying incretin secretion (GLP-1, GIP), and accelerating glucose disposal in the immediate postprandial period (Nilsson et al., 2007; Connolly et al., 2023; Bell et al., 2025). Such meal-timed insulinotropic effects are central to preventing exaggerated or prolonged post-meal glucose excursions, which are tightly linked to the progression of metabolic syndrome and type 2 diabetes.

A key mechanistic advantage of WPC80 lies in its ability to compensate for impaired first-phase insulin secretion, a hallmark defect in early insulin resistance. In insulin-resistant individuals, pancreatic β-cells are not fundamentally dysfunctional; rather, the rapid release of preformed insulin granules that normally occurs within minutes of carbohydrate ingestion is blunted (Akhavan et al., 2014; King et al., 2018). As a result, glucose rises sharply because β-cells must rely on slower, de novo insulin synthesis to manage the carbohydrate load. WPC80 effectively bypasses this impaired early-phase response. Its rapid aminoacidemia enhances β-cell ATP production, closes KATP channels, triggers calcium-mediated insulin exocytosis, and provokes a robust incretin response, producing an insulin signal that is both earlier and stronger than that triggered by carbohydrate ingestion alone in insulin-resistant states (Hamarsland et al., 2019; Nilsson et al., 2007; Mohammadi et al., 2023). Consequently, consuming WPC80 before or with meals mimics and restores the timing of healthy first-phase insulin secretion, lowering postprandial glucose excursions and improving overall glycemic stability (Frid et al., 2005; Jakubowicz & Froy, 2013; Connolly et al., 2023). MPC, by contrast, produces a muted and delayed amino acid signal that is often insufficient to support timely glucose clearance, particularly in individuals with impaired insulin action (Mitchell et al., 2015; Tenenbaum et al., 2023).

Clinical evidence consistently demonstrates the therapeutic value of this mechanism. Randomized trials and systematic reviews show that WPC80 consumed before or with meals lowers postprandial glucose, reduces fasting insulin, improves insulin sensitivity (as measured by HOMA-IR), and decreases HbA1c in individuals with prediabetes, metabolic syndrome, and insulin resistance (Amirani et al., 2020; Chiang et al., 2022; Connolly et al., 2023; Bell et al., 2025; Mohammadi et al., 2023). These improvements occur despite WPC80's strong insulinotropic effect, underscoring that physiologically timed, meal-associated insulin release is metabolically beneficial, not harmful, in individuals with impaired early-phase insulin dynamics. Furthermore, post-exercise ingestion of WPC80 facilitates glycogen repletion, augments muscle anabolism, and supports improved insulin sensitivity, adding another dimension to its metabolic benefits (Mehra et al., 2021; Tang et al., 2009; West et al., 2017).

Nevertheless, the metabolic impact of WPC80 depends on dietary context. Potential drawbacks arise primarily when whey protein is combined with large quantities of rapidly absorbed carbohydrates. Under these circumstances, the combined glycemic and amino acid stimulus may produce transient postprandial hypoglycemia in sensitive individuals or increase total daily insulin exposure if such patterns are habitual (Hamarsland et al., 2017; Bell et al., 2025). Similar concerns apply to excessive, repeated supplementation throughout the day (e.g., three to five servings in sedentary individuals), which may generate unnecessary acute insulin pulses and transiently suppress fat oxidation (Chiu et al., 2014; Bell et al., 2025). Importantly, these scenarios represent misapplication rather than inherent flaws in WPC80. Under evidence-based, meal-timed use, WPC80 consistently improves, rather than worsens, glycemic control, even in insulin-resistant individuals.

In contrast, MPC's slow casein-dominant digestion results in a muted leucine response and a delayed insulin and incretin profile that provides limited support for rapid postprandial glucose disposal. For individuals with impaired first-phase insulin release, representing at least half of adults in Western populations, this slower kinetic profile is suboptimal, as it fails to produce a sufficiently timely insulin signal to manage carbohydrate-induced glycemic excursions (Mitchell et al., 2015; Tenenbaum et al., 2023). Consequently, MPC lacks the targeted metabolic benefits associated with WPC80 and is less suited for individuals with insulin resistance, prediabetes, or metabolic syndrome, precisely the populations for whom metabolic regulation is most critical.

B. The Role of Incretins (GLP-1) and DPP-IV Inhibition in WPC

WPC also improves postprandial glucose control through its effects on the incretin system, a key endocrine pathway governing insulin release and gastric emptying (Connolly et al., 2023). Upon reaching the small intestine, digested whey peptides stimulate the secretion of the gut hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) (Connolly et al., 2023; Tenenbaum et al., 2023). GLP-1 is particularly important because it enhances glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying, three coordinated actions that help prevent large post-meal glucose excursions and improve overall glycemic stability (Tenenbaum et al., 2023).

Experimental models demonstrate that whey proteins—especially hydrolyzed or enzymatically pre-digested fractions, elicit a robust GLP-1 response. For example, digested whey protein hydrolysate (WPH) induces a markedly higher GLP-1 release in enteroendocrine cells compared to whey protein isolate (WPI), highlighting the bioactivity that emerges during whey digestion (Tenenbaum et al., 2023). These mechanisms are directly relevant to WPC80, which generates similar bioactive peptide fragments during human digestion.

In addition to stimulating incretin secretion, whey-derived peptides act as natural inhibitors of dipeptidyl peptidase-4 (DPP-IV), the enzyme responsible for rapidly degrading active GLP-1 (Connolly et al., 2023; Tenenbaum et al., 2023). By slowing GLP-1 breakdown, WPC prolongs the hormone's action, amplifying and extending its insulinotropic and gastric-slowing effects. This dual action—enhanced GLP-1 release combined with DPP-IV inhibition—creates a powerful and physiologically balanced mechanism for postprandial glycemic control. The slower-digesting MPC lacks this rapid peptide-driven incretin response and therefore provides inferior metabolic support (Bell et al., 2025; Connolly et al., 2023).

C. Evidence from Meta-Analyses on Glycemic Control and Dyslipidemia

The chronic benefits of WPC supplementation in high-risk populations, those who are overweight, obese, or diagnosed with metabolic syndrome, are supported by robust systematic reviews and meta-analyses (Connolly et al., 2023; Amirani et al., 2020). These studies confirm that WPC significantly improves multiple clinical indicators:

- **Insulin Resistance:** WPC supplementation is associated with favorable reductions in fasting insulin, HOMA-IR, and HbA1c (Connolly et al., 2023; Amirani et al., 2020).
- **Dyslipidemia:** WPC significantly lowers circulating triglycerides, total cholesterol, and LDL-cholesterol, while also reducing the total cholesterol/HDL-cholesterol ratio (Connolly et al., 2023; Amirani et al., 2020).

While general milk protein supplementation (MPC) also shows favorable effects on some glycemic parameters, such as fasting blood glucose and HbA1c, the evidence often carries low certainty and must be weighed against the intrinsic tolerability issues posed by the high lactose and galactose content in MPC for LNP populations (Mohammadi et al., 2023). Furthermore, the chronic metabolic improvements induced by WPC in high-risk populations occur concomitantly with the reduction in systemic inflammation mediated by its bioactive peptides and improved gut barrier integrity (Olsen et al., 2023; Connolly et al., 2023).

IV. Anabolic Efficacy and Counteracting Age-Related Anabolic Resistance

For maintaining muscle mass, particularly in aging populations susceptible to anabolic resistance and sarcopenia, the rapid delivery kinetics of WPC 80 provide a distinct advantage (Mitchell et al., 2015; Pinckaers et al., 2022).

A. Acute Kinetic Response: WPC vs. MPC

Muscle protein synthesis (MPS) is maximally stimulated by a rapid surge of essential amino acids into the bloodstream, establishing the "leucine threshold" model (Mitchell et al., 2015). The goal in supplementing individuals, especially those with anabolic resistance, is to achieve this maximal plasma peak as quickly and completely as possible (Hamarsland et al., 2017). As demonstrated by multiple acute comparative studies, WPC achieves a greater and faster peak of leucine and essential amino acids compared to MPC (Hamarsland et al., 2019). This difference is entirely attributable to the slower-digesting nature of casein in MPC, which prolongs amino acid availability but compromises the critical magnitude of the peak required to overcome resistance (Mitchell et al., 2015; Pinckaers et al., 2022).

B. Long-Term Adaptations in Strength Training (WPC vs. Milk)

While acute kinetic responses favor WPC, long-term studies comparing the effects of WPC against milk protein supplementation in strength training often report similar outcomes for overall muscle mass and strength gains when the training protocol is well-executed and protein intake is sufficient (Hamarsland et al., 2019). For instance, a randomized controlled trial comparing native whey versus spray-dried milk supplementation (20g protein daily) during a 12-week resistance training program in untrained young adults found no differential effect between the groups on long-term adaptations in muscle mass or strength (Hamarsland et al., 2019).

However, it is crucial to interpret these findings in context: such parity suggests that for healthy, younger individuals consuming adequate protein and engaged in rigorous training, the minimal physiological differences between the fast-acting whey and the composite milk protein are overcome by the potent, overarching stimulus of the exercise itself (Hamarsland et al., 2019). In environments where the dose is lower, where the timing is compromised, or where the individual is compromised by anabolic resistance (such as older adults or patients undergoing recovery), the kinetic superiority of WPC becomes decisive (Pinckaers et al., 2022; Mitchell et al., 2015).

C. The Imperative for Rapid EAA (essential amino acid) Delivery in Sarcopenia Management

Anabolic resistance necessitates higher doses and/or faster-acting proteins to initiate the MPS response (Mitchell et al., 2015). The slow digestion and attenuated amino acid peak of MPC are disadvantages when aiming to maximize anabolism in older, sarcopenic individuals (Pinckaers et al., 2022). WPC 80, delivering a maximal leucine and EAA bolus, ensures the most potent possible anabolic signal, regardless of the individual's underlying sensitivity to protein (Hamarsland et al., 2017).

Therefore, while both WPC and MPC may be effective for healthy young athletes, for the critical public health goals of maintaining muscle mass and promoting recovery in the vulnerable and aging majority, the superior kinetics and enhanced physiological signal of WPC 80 establish it as the functionally essential protein choice (Mitchell et al., 2015; Mehra et al., 2021).

V. Rethinking "Naturalness": MPC, WPC80, and Human Biology

A persistent narrative in both consumer marketing and some clinical settings is that MPC is a more "natural" or "whole-food–like" option than whey protein concentrates, whereas WPC80 is perceived as a more "processed" and "fast-acting" fraction. A closer examination of dairy biochemistry, human digestive physiology, and industrial processing reveals that this assumption is not only misleading but, in many respects, inverted. From the standpoint of global lactose tolerance, gut barrier protection, and alignment with human protein physiology, cheese-derived WPC80 is arguably the more biologically appropriate and functionally "natural" choice for most of the world's population (Mehra et al., 2021; Misselwitz et al., 2019).

Whole bovine milk contains roughly 80% casein and 20% whey proteins, whereas human breast milk is characteristically whey-dominant (approximately 60:40 whey to casein), reflecting an evolutionary priority for rapidly absorbed, bioactive whey proteins during early life (Mehra et al., 2021). In cheese production, bovine milk undergoes rennet-induced coagulation of κ-casein, forming curds rich in casein and a liquid whey fraction enriched in whey proteins and the glycosylated peptide glycomacropeptide (GMP) (Barbano et al., 2010; Rackerby et al., 2024; Adler et al., 2023). WPC80 is produced by ultrafiltration and concentration of this cheese whey, yielding a powder that is essentially a purified form of the whey fraction that already exists in milk, and which more closely resembles the whey-rich protein profile of human milk than casein-dominant MPC (Mehra et al., 2021; Rackerby et al., 2024).

By contrast, MPC is manufactured by ultrafiltration of skim milk, concentrating casein, whey, and lactose together while largely preserving the 80:20 casein-to-whey ratio and much of milk's intrinsic sugar load (Mehra et al., 2021). The resulting powder is not simply "dried milk"; rather, it is an industrially concentrated casein–lactose matrix with substantially higher lactose density per unit of protein, reduced buffering from the native fat matrix, and a markedly different digestive profile from either whole milk or cheese. Crucially, the cheese-making step that generates GMP and separates lactose into the whey and permeate streams does not occur in MPC production; as a result, MPC lacks the cheese-derived GMP fraction and maintains a fermentable carbohydrate burden that is poorly tolerated by the majority of adults worldwide (Barbano et al., 2010; Misselwitz et al., 2019; Rackerby et al., 2024).

From a physiological perspective, this distinction is non-trivial. Approximately 65–70% of the global adult population is lactase non-persistent and experiences dose-dependent gastrointestinal symptoms, bloating, cramping, diarrhea, when exposed to even moderate lactose loads (Misselwitz et al., 2019). MPC, by concentrating lactose alongside casein, delivers a disproportionately high fermentable carbohydrate burden relative to its protein content. In individuals with lactase non-persistence or subclinical lactose malabsorption, this excess lactose can be rapidly fermented in the colon, driving gas production, luminal distension, osmotic diarrhea, and downstream increases in intestinal permeability and low-grade inflammation (Misselwitz et al., 2019; Oliveira et al., 2022). Thus, far from being benign or "food-like," MPC often functions as a concentrated delivery vehicle for a sugar that a large proportion of adults cannot efficiently digest.

In contrast, cheese-derived WPC80 typically contains only trace amounts of residual lactose and galactose because most sugars are removed with the whey permeate during filtration (Mehra et al., 2021; Evans et al., 2012). This markedly lowers the fermentable carbohydrate burden per serving and dramatically improves tolerability in lactase non-persistent and irritable bowel phenotypes, while still delivering a full complement of rapidly absorbed whey proteins and cheese-derived bioactives such as GMP and immunoglobulins (Rackerby et al., 2024; Adler et al., 2023). From the standpoint of gut comfort and barrier protection, WPC80 is therefore more compatible with the gastrointestinal physiology of the average adult than MPC, which remains constrained by the global epidemiology of lactose malabsorption (Misselwitz et al., 2019).

The notion that WPC80 is somehow "unnatural" because it is fast-digesting also does not withstand mechanistic scrutiny. The rapid gastric emptying and proteolysis of whey proteins are inherent properties of the whey fraction in native milk, not artifacts of processing (Mehra et al., 2021). In mammalian physiology, whey's rapid aminoacidemia supports early-life growth, immune signaling, and metabolic regulation, while casein's clotting behavior provides sustained amino acid release. WPC80, as a purified whey fraction derived from cheese whey, simply concentrates this naturally fast-acting protein class; it does not create a novel or non-physiological entity. Conversely, MPC's dense concentration of casein and lactose without the mitigating presence of whole-milk fat or cheese-derived GMP represents a configuration not commonly encountered in traditional dietary patterns and one that is metabolically and gastrointestinally challenging for many individuals.

When these compositional realities are integrated with the mechanistic domains outlined earlier, gastrointestinal tolerance, bioactive peptide content, metabolic regulation, and anabolic signaling, a coherent picture emerges. WPC80 offers a whey-dominant, low-lactose, bioactive-rich protein source that aligns more closely with human milk physiology, global patterns of lactose tolerance, and contemporary needs related to insulin resistance and sarcopenia. MPC, despite its intuitive appeal as "whole milk in powder form," amplifies exactly those components, lactose and casein, that are least compatible with the digestive capacity and metabolic health profile of most adults. Reframing the discussion in this way suggests that, for the majority of real-world consumers, cheese-derived WPC80 is not only functionally superior but arguably more "natural" in the sense that it harmonizes with human physiology rather than challenging it.

VI. The A1/A2 Casein Distinction: Implications for Dairy Protein Tolerance, Inflammation, and the Gut Microbiome

Dairy protein genetics have become a critical area of nutritional science, with growing attention on the functional distinctions between A1 and A2 β-casein and their downstream effects on gut tolerance, inflammation, and microbiome composition. These differences are particularly relevant when selecting between MPC and WPC80, which differ not only in digestion kinetics but also in their casein content and BCM-7–producing potential (Jeong et al., 2023; Shukla et al., 2024).

A. Genetic Variants and Digestion: Why A1 Differs From A2

β-casein accounts for roughly 30% of total milk protein and exists in at least 13 genetic variants, with A1 and A2 being the most prevalent. A2 represents the ancestral form, whereas A1 emerged from a relatively recent point mutation in northern European cattle breeds (Kaminski et al., 2007). The functional difference lies in a single amino acid substitution at position 67: proline in A2 is replaced with histidine in A1. This change alters the peptide's structural conformation and makes the adjacent bond susceptible to gastrointestinal enzymatic cleavage, releasing β-casomorphin-7 (BCM-7) from A1 digestion, whereas A2 resists this cleavage (Jeong et al., 2023; Kamiński et al., 2025).

BCM-7 is an opioid peptide capable of binding μ-opioid receptors in the gut, modulating motility, immune activity, and epithelial function. Animal and cell studies show that BCM-7 can slow intestinal transit, increase gut inflammatory markers, and modify microbial metabolic outputs; human trials increasingly report similar effects, particularly in individuals with underlying gastrointestinal sensitivities (Gonzales-Malca et al., 2023; Jianqin et al., 2016; Song et al., 2025).

B. MPC vs WPC80: A1 Content and Tolerance

These distinctions are highly relevant when comparing MPC and WPC80. MPC is made from concentrated milk and retains the full casein fraction, including both A1 and A2 variants, at their typical ratio of 80% casein to 20% whey. Unless explicitly sourced from A2-only herds, commercial MPC nearly always contains A1 β-casein, especially when derived from Holstein and other European breeds (Shukla et al., 2024; Kamiński et al., 2025).

In contrast, WPC80 is produced from cheese whey, the soluble fraction that remains after casein coagulates during cheese making. This process removes nearly all casein proteins, including A1 and A2 variants, leaving only trace amounts in the final product (Barbano et al., 2010; Giribaldi et al., 2022). Because casein is the sole precursor of BCM-7, WPC80 contains negligible amounts of BCM-7–forming peptides and is therefore functionally more similar to A2-only dairy products. This distinction helps explain why many individuals who cannot tolerate MPC can consume WPC80 without gastrointestinal distress.

C. Gut Inflammation, Microbiome Alterations, and Systemic Immune Effects

Growing evidence implicates A1 β-casein, and more specifically BCM-7, in promoting low-grade gastrointestinal inflammation and microbiome disruptions. BCM-7 slows intestinal transit, increases gut permeability, activates local immune pathways, and elevates fecal inflammatory markers such as calprotectin (Jianqin et al., 2016; Choi et al., 2024; Song et al., 2025). Human crossover studies consistently show that A1 β-casein consumption produces greater GI discomfort, stool inconsistency, and inflammatory biomarker elevations compared to A2 β-casein.

Conversely, switching to A2 milk, or to low-casein whey products such as WPC80, improves tolerance, decreases inflammation, and promotes healthier shifts in microbial composition (Jianqin et al., 2016; Song et al., 2025). Beneficial bacteria including *Bifidobacterium* and *Blautia* increase, while pro-inflammatory taxa decline (Jeong et al., 2023). Improvements in epithelial integrity and barrier function have also been documented following removal of A1 β-casein from the diet (Song et al., 2025).

Importantly, these outcomes are mediated not only by the removal of inflammatory casein fragments but also by the presence of beneficial whey components, particularly glycomacropeptide (GMP)—which exert prebiotic and anti-inflammatory effects (Arza et al., 2021; Dallas et al., 2023).

D. Broader Health Implications Beyond the Gut

Reducing A1-derived BCM-7 exposure may offer systemic benefits, including decreased low-grade inflammation, reduced immune activation, and improved metabolic function (Kamiński et al., 2025; Jeong et al., 2023). Some preliminary work suggests potential neuroinflammatory and neurobehavioral impacts of BCM-7 exposure, though further human research is required (Shukla et al., 2024; Gonzales-Malca et al., 2023). In contrast, whey-derived proteins found in WPC80 are linked to improved muscle protein synthesis, better glycemic control, antioxidant support, and minimal inflammatory signaling (Barbano et al., 2010; Dallas et al., 2023).

Discussion

The detailed comparative analysis of MPC and cheese-derived Whey Protein Concentrates (WPC80 and WPC90/WPI) demonstrates that differing manufacturing pathways produce fundamentally distinct nutritional, gastrointestinal, and metabolic outcomes. The evidence strongly supports the conclusion that WPC, particularly WPC80, offers functional advantages over MPC for optimizing general and clinical nutrition in most adult populations.

Gastrointestinal Tolerability and Bioactive Superiority

The primary limitation of MPC lies in its high load of fermentable carbohydrates (lactose and galactose), retained during membrane concentration alongside the native 80:20 casein:whey ratio (Mehra et al., 2021). This composition directly conflicts with the physiology of the ~70% of the global population affected by lactase non-persistence (Misselwitz et al., 2019). In such individuals, undigested lactose reaches the colon, where bacterial fermentation produces gas, osmotic load, and microbial shifts that compromise gut barrier integrity, often resulting in bloating, discomfort, and inflammation (Oliveira et al., 2022).

WPC80 and WPC90, in contrast, virtually eliminate this pathological cascade by drastically reducing residual sugars during cheese whey processing and subsequent filtration (Evans et al., 2012). The near absence of fermentable carbohydrate burden significantly improves tolerance and protects the epithelial barrier.

Crucially, the processing distinction also gives WPC80 a unique bioactive advantage. Both WPC80 and WPC90 begin as liquid whey rich in Glycomacropeptide (GMP), a hydrophilic O-glycopeptide released during rennet-mediated cleavage of κ-casein (Rackerby et al., 2024). GMP constitutes roughly 20% of the mass of WPC products and serves as a potent prebiotic substrate selectively utilized by Bifidobacterium and Lactobacillus, promoting beneficial cross-feeding networks within the microbiome (González-Morelo & Garrido, 2024; Rackerby et al., 2024). Digested whey peptides, including those derived from GMP, also exert anti-inflammatory effects, suppressing tumor necrosis factor-α (TNF-α) and mitigating mucosal immune activation (Olsen et al., 2023).

While WPC90 undergoes additional purification (e.g., microfiltration or ion exchange) to exceed 90% protein concentration, this refinement reduces fat, minerals, and bioactive peptide content, including GMP (Barbano et al., 2010). As a result, WPC80, being less extensively processed, retains the richest spectrum of gut-modulating bioactives. This profile offers superior benefits for microbial homeostasis and anti-inflammatory signaling when compared to both WPC90 and GMP-absent MPC (Barbano et al., 2010).

The A1/A2 β-Casein Distinction

Another major differentiator between MPC and WPC lies in their β-casein content. MPC retains nearly all casein, including A1 β-casein when sourced from common breeds such as Holstein

(Kamiński & Cieślińska, 2025; Shukla et al., 2024). A1 β-casein releases β-casomorphin-7 (BCM-7), an opioid peptide linked to slowed intestinal transit, increased permeability, elevated fecal calprotectin, and greater gastrointestinal discomfort (Choi et al., 2024; Jianqin et al., 2016). BCM-7 also engages μ-opioid receptors within the gut, modulating motility and immune activation.

WPC80 and WPC90, however, originate from the soluble whey fraction remaining after casein coagulation during cheese production. This process removes nearly all casein—including both A1 and A2 β-casein variants—and therefore eliminates the precursor for BCM-7 formation (Giribaldi et al., 2022). Functionally, this makes both WPC forms akin to A2-only dairy in terms of casein digestibility and BCM-7 exposure, offering substantial advantages for individuals who experience milk-related discomfort (Song et al., 2025).

Metabolic Signaling and Anabolic Efficacy

WPC80 and WPC90 also confer clear metabolic and anabolic benefits compared to MPC. Due to rapid digestion kinetics, WPC ingestion produces a fast and high peak in essential amino acids, particularly leucine, resulting in a strong and immediate anabolic signal (Hamarsland et al., 2019). This rapid aminoacidemia is necessary to overcome age-related anabolic resistance, making WPC especially valuable for aging adults, sarcopenic populations, and those recovering from illness or immobilization (Mitchell et al., 2015; Pinckaers et al., 2022). By contrast, the slow gastric clotting of MPC leads to a prolonged but attenuated amino acid rise that is less effective at maximizing muscle protein synthesis.

WPC also has superior effects on glycemic control. Its rapid peptide influx stimulates incretin secretion, GLP-1 and GIP, and inhibits Dipeptidyl Peptidase-4 (DPP-IV), increasing the half-life and bioactivity of GLP-1 (Connolly et al., 2023; Tenenbaum et al., 2023). This coordinated response restores first-phase insulin secretion, reduces postprandial glucose excursions, and improves metabolic markers such as HOMA-IR and HbA1c in individuals with prediabetes and metabolic syndrome (Amirani et al., 2020; Connolly et al., 2023). MPC, lacking rapid peptide-driven signaling due to its casein-dominant profile, does not offer these acute metabolic benefits and is metabolically inferior for individuals needing improved postprandial control (Bell et al., 2025).

Conclusion

The collective evidence demonstrates that cheese-derived WPC80 is functionally, mechanistically, and clinically superior to MPC for the vast majority of adult populations. The primary limitation of MPC lies in its high fermentable carbohydrate load, specifically lactose and galactose, which poses significant tolerability challenges for the global majority affected by lactase non-persistence. In these individuals, MPC frequently precipitates gastrointestinal discomfort, gas, bloating, and downstream barrier disruption, contributing to inflammatory signaling and metabolic impairment (Misselwitz et al., 2019; Oliveira et al., 2022).

WPC80 avoids this pathological cascade by eliminating most fermentable sugars through cheese-whey processing and ultrafiltration, while simultaneously providing a unique constellation of bioactive peptides and metabolic advantages. Its superiority arises from several converging properties. First, WPC80 features a markedly reduced carbohydrate burden, substantially improving gastrointestinal compatibility and long-term compliance. Second, it uniquely contains glycomacropeptide (GMP), a potent prebiotic and immunomodulatory glycopeptide absent from MPC, which promotes microbial homeostasis, enhances bifidogenic activity, and suppresses mucosal inflammation (Rackerby et al., 2024; Olsen et al., 2023).

Third, WPC80 exhibits rapid digestion kinetics and superior essential amino acid bioavailability, generating robust aminoacidemia and potentiating incretin signaling (GLP-1, GIP). These mechanisms collectively support improved insulin sensitivity, more efficient postprandial glucose regulation, and meaningful reductions in cardiometabolic risk factors, including HOMA-IR and HbA1c (Connolly et al., 2023; Bell et al., 2025). Fourth, WPC80's rapid leucine delivery optimally stimulates muscle protein synthesis and effectively combats age-related anabolic resistance, an essential consideration for aging adults, sarcopenic individuals, and those recovering from illness (Hamarsland et al., 2021; Pinckaers et al., 2022).

Furthermore, unlike MPC, which retains A1 β-casein and therefore introduces the potential for BCM-7–mediated gastrointestinal and inflammatory effects, WPC80 contains only negligible trace amounts of casein. This functional absence of A1 β-casein and BCM-7 precursors confers additional tolerability advantages, especially for individuals with casein sensitivity, IBS-like symptoms, or gut-permeability disorders.

Taken together, these findings establish that WPC80 is not merely a lactose-free alternative, nor simply a "faster protein," but a mechanistically distinct nutritional substrate offering superior gastrointestinal tolerance, bioactive functionality, metabolic regulation, and anabolic efficacy. As such, cheese-derived WPC80 represents a scientifically validated, physiologically harmonious, and globally accessible protein source. For individuals seeking an evidence-based strategy that promotes gut integrity, metabolic resilience, and muscle health across the lifespan, the functional superiority of WPC80 over MPC remains unequivocal.

References

Adams, R. L., & Broughton, K. S. (2016). Insulinotropic Effects of Whey: Mechanisms of Action, Recent Clinical Trials, and Clinical Applications. In Annals of Nutrition and Metabolism (Vol. 69, Issue 1, pp. 56–63). S. Karger AG. https://doi.org/10.1159/000448665

Adler, S. M., Paluska, M. R., Svoboda, K. R., & Dallas, D. C. (2023). *Immunomodulatory bioactivities of glycomacropeptide. Comprehensive Reviews in Food Science and Food Safety, 22*(2), 1969–1992. https://doi.org/10.1111/1541-4337.13157

Akhavan, T., Luhovyy, B. L., Panahi, S., Kubant, R., Brown, P. H., & Anderson, G. H. (2014). Mechanism of action of pre-meal consumption of whey protein on glycemic control in young adults. Journal of Nutritional Biochemistry, 25(1), 36–43. https://doi.org/10.1016/j.jnutbio.2013.08.012

Amirani, E., Milajerdi, A., Reiner, Ž., Mirzaei, H., Mansournia, M. A., & Asemi, Z. (2020). Effects of whey protein on glycemic control and serum lipoproteins in patients with metabolic syndrome and related conditions: A systematic review and meta-analysis of randomized controlled clinical trials. In Lipids in Health and Disease (Vol. 19, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12944-020-01384-7

Anguita-Ruiz, A., Aguilera, C. M., & Gil, Á. (2020). Genetics of lactose intolerance: An updated review and online interactive world maps of phenotype and genotype frequencies. In Nutrients (Vol. 12, Issue 9, pp. 1–20). MDPI AG. https://doi.org/10.3390/nu12092689

Arza, C. B., Cardozo-Filho, L., Lima, J. C., et al. (2021). Whey proteins are more efficient than casein in the recovery of muscle functional properties following a casting induced muscle atrophy. *PLoS ONE*, *8*(9), e75408. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0075408

Barbano, D. M., Zulewska, J., Newbold, M., Evans, M., & Drake, M. A. (2010). Comparison of composition and sensory properties of 80% whey protein and milk serum protein concentrates. Journal of Dairy Science, 93(4), 1824–1843. https://doi.org/10.3168/jds.2009-2723

Bell, H. L., Jackson, K. G., Crompton, L. A., Givens, D. I., & Lovegrove, J. A. (2025). The impact of whey protein on plasma branched-chain amino acids and glycaemic control in humans. A narrative review. In Nutrition Research Reviews. Cambridge University Press. https://doi.org/10.1017/S0954422425100140

Chiang, S. W., Liu, H. W., Loh, E. W., Tam, K. W., Wang, J. Y., Huang, W. L., & Kuan, Y. C. (2022). Whey protein supplementation improves postprandial glycemia in persons with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Nutrition Research, 104, 44–54. https://doi.org/10.1016/j.nutres.2022.04.002

Chiu, S., Williams, P. T., Dawson, T., Bergman, R. N., Stefanovski, D., Watkins, S. M., & Krauss, R. M. (2014). Diets high in protein or saturated fat do not affect insulin sensitivity or plasma concentrations of lipids and lipoproteins in overweight and obese adults. Journal of Nutrition, 144(11), 1753–1759. https://doi.org/10.3945/jn.114.197624

Choi, Y., Kim, N., Song, C. H., et al. (2024). The effect of A2 milk on gastrointestinal symptoms in comparison to A1/A2 milk: a single-center, randomized, double-blind, cross-over study. *Journal of Cancer Prevention*, *29*(2), 45–53. https://doi.org/10.15430/JCP.24.007

Connolly, G., Wang, Y., Bergia, R. E., & Campbell, W. W. (2023). Whey Protein Supplementation and Type 2 Diabetes Mellitus Risk Factors: An Umbrella Systematic Review of Randomized Controlled Trials. *Current Developments in Nutrition*, 7(12), 100008. https://doi.org/10.1016/j.cdn.2023.100008

Dallas, D. C., et al. (2023). Macrophage-Immunomodulatory Actions of Bovine Whey Protein Isolate, Glycomacropeptide, and Their In Vitro and In Vivo Digests. *Nutrients*, *15*(23), 4942. https://doi.org/10.3390/nu15234942

Evans, J., Zulewska, J., Newbold, M., Drake, M. A., & Barbano, D. M. (2012). *Comparison of composition and sensory properties of 80% whey protein and milk serum protein concentrates. Journal of Dairy Science, 95*(12), 6886–6898. https://doi.org/10.3168/jds.2012-5813

Fung, M., Xue, X., & Szilagyi, A. (2020). Estimating lactase nonpersistence distributions in the multi-ethnic canadian demographic: A population-based study. Journal of the Canadian Association of Gastroenterology, 3(3), 103–110. https://doi.org/10.1093/jcag/gwy068

Frid, A. H., Nilsson, M., Holst, J. J., & Björck, I. M. E. (2005). Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. *American Journal of Clinical Nutrition*, *82*(1), 69–75. https://pubmed.ncbi.nlm.nih.gov/16002802/

Gallo, V., Arienzo, A., Tomassetti, F., & Antonini, G. (2024). Milk Bioactive Compounds and Gut Microbiota Modulation: The Role of Whey Proteins and Milk Oligosaccharides. In Foods (Vol. 13, Issue 6). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/foods13060907

Gerbault P, Liebert A, Itan Y, Powell A, Currat M, Burger J, Swallow DM, Thomas MG. Evolution of lactase persistence: an example of human niche construction. Philos Trans R Soc Lond B Biol Sci. 2011 Mar 27;366(1566):863-77. doi: 10.1098/rstb.2010.0268. PMID: 21320900; PMCID: PMC3048992https://www.researchgate.net/publication/49835907_Evolution_of_lactase_persistence_An_example_of_human_niche_construction

Giribaldi, M., Lamberti, C., & Cavallarin, L. (2022). A2 milk and BCM-7 peptide as emerging parameters of milk quality. *Frontiers in Nutrition*, *9*, 842375. https://doi.org/10.3389/fnut.2022.842375

Gonzales-Malca, J. A., Tirado-Kulieva, V. A., Abanto-López, M. S., et al. (2023). Worldwide research on the health effects of bovine milk containing A1 and A2 β-casein: Unraveling the current scenario and future trends through bibliometrics and text mining. *Current Research in Food Science*, *6*, 100434.

González-Morelo, K. J., & Garrido, D. (2024). Cross-feeding interactions of gut microbes mediated by O-linked glycans from casein glycomacropeptide. Journal of Functional Foods, 118. https://doi.org/10.1016/j.jff.2024.106269

Hamarsland, H., Laahne, J. A. L., Paulsen, G., Cotter, M., Børsheim, E., & Raastad, T. (2017). Native whey induces higher and faster leucinemia than other whey protein supplements and milk: A randomized controlled trial. BMC Nutrition, 3(1). https://doi.org/10.1186/s40795-017-0131-9

In vitro comparison of whey protein isolate and hydrolysate for their effect on glucose homeostasis markers. (2023). *Food & Function*, 14, 4173–4182. https://doi.org/10.1039/d3fo00467h

Jakubowicz, D., & Froy, O. (2013). Biochemical and metabolic mechanisms by which dietary whey protein may combat obesity and Type 2 diabetes. *The Journal of Nutritional Biochemistry*, *24*(1), 1–5. https://doi.org/10.1016/j.jnutbio.2012.07.008

Jakubowicz, D., Froy, O., Ahrén, B., Boaz, M., Landau, Z., Bar-Dayan, Y., Ganz, T., Barnea, M., & Wainstein, J. (2014). Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: A randomised clinical trial. *Diabetologia*, *57*(9), 1807–1811. https://doi.org/10.1007/s00125-014-3305-x

Jeong, H., Park, Y. S., & Yoon, S. S. (2023). A2 milk consumption and its health benefits: an update. *Food Science and Biotechnology*, *33*, 491–503. https://doi.org/10.1007/s10068-023-01428-5

Jianqin, S., Leiming, X., Lu, X., Yelland, G. W., Ni, J., & Clarke, A. J. (2016). Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cows' milk. *Nutrition Journal*, *15*, 35. https://doi.org/10.1186/s12937-016-0147-z

Kamiński, S., Cieślińska, A., & Kostyra, E. (2007). Polymorphism of bovine beta-casein and its potential effect on human health. *Journal of Applied Genetics*, *48*(3), 189–198.

King, D. G., Walker, M., Campbell, M. D., Breen, L., Stevenson, E. J., & West, D. J. (2018). A small dose of whey protein co-ingested with mixed-macronutrient breakfast and lunch meals improves postprandial glycemia and suppresses appetite in men with type 2 diabetes: A randomized controlled trial. American Journal of Clinical Nutrition, 107(4), 550–557. https://doi.org/10.1093/ajcn/nqy019

Kamiński, S., & Cieślińska, A. (2025). β-Casein A1 and A2 genetic variants and β-casomorphin-7 in raw milk and processed milk products. *International Journal of Molecular Sciences*, *26*(8612), 1–15. https://doi.org/10.3390/ijms26218612

Li, W., Sun, K., Ji, Y., Wu, Z., Wang, W., Dai, Z., & Wu, G. (2016). Glycine regulates expression and distribution of claudin-7 and Zo-3 proteins in intestinal porcine epithelial cells. Journal of Nutrition, 146(5), 964–969. https://doi.org/10.3945/jn.115.228312

Lima, J. C., Seixas, F. A. V., Coimbra, J. S. R., Pimentel, T. C., Barão, C. E., & Cardozo-Filho, L. (2019). Continuous fractionation of whey protein isolates by using supercritical carbon dioxide. Journal of CO2 Utilization, 30, 112–122. https://doi.org/10.1016/j.jcou.2019.01.008

Ioannou, M., Borkent, J., Severance, E. G., Yolken, R. H., Fasano, A., Sommer, I. E. C., & Haarman, B. C. M. (2025). Biomarkers of intestinal permeability in major psychiatric disorders: Distinct biological roles call for a more nuanced application. In Progress in Neuro-Psychopharmacology and Biological Psychiatry (Vol. 139). Elsevier Inc. https://doi.org/10.1016/j.pnpbp.2025.111405

Mehra, R., Kumar, H., Kumar, N., Sharma, K., & Bhatnagar, R. (2021). Whey proteins processing and emergent derivatives: An insight perspective from constituents, bioactivities, functionalities to therapeutic applications. *Journal of Functional Foods*, 87, 104781. https://doi.org/10.1016/j.jff.2021.104781

Milk Bioactive Compounds and Gut Microbiota Modulation: The Role of Whey Proteins and Milk Oligosaccharides. (2022). *International Journal of Molecular Sciences*, 23(7), 3907. https://doi.org/10.3390/ijms23073907

Misselwitz, B., Butter, M., Verbeke, K., & Fox, M. R. (2019). Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management. *Gut*, 68(11), 2083–2091. https://doi.org/10.1136/gutjnl-2019-318404

Mitchell, C. J., McGregor, R. A., D’Souza, R. F., Thorstensen, E. B., Markworth, J. F., Fanning, A. C., Poppitt, S. D., & Cameron-Smith, D. (2015). Consumption of milk protein or whey protein results in a similar increase in muscle protein synthesis in middle aged men. Nutrients, 7(10), 8685–8699. https://doi.org/10.3390/nu7105420

Mohammadi, S., Asbaghi, O., Dolatshahi, S., Omran, H. S., Amirani, N., Koozehkanani, F. J., Garmjani, H. B., Goudarzi, K., & Ashtary-Larky, D. (2023). Effects of supplementation with milk protein on glycemic parameters: a GRADE-assessed systematic review and dose–response meta-analysis. In Nutrition Journal (Vol. 22, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12937-023-00878-1

Nilsson, M., Holst, J. J., & Björck, I. M. E. (2007). Metabolic effects of amino acid mixtures and whey protein in healthy subjects: Studies using glucose-equivalent drinks. *American Journal of Clinical Nutrition*, *85*(4), 996–1004. https://pubmed.ncbi.nlm.nih.gov/17413098/

Oliveira, L. S., Wendt, G. W., Crestani, A. P. J., & Carpes, S. T. (2022). The use of probiotics and prebiotics can enable the ingestion of dairy products by lactose intolerant individuals. *Clinical Nutrition*, 41(12), 2533–2539. https://doi.org/10.1016/j.clnu.2022.10.008

Olsen, A. J., Stojiljkovic, S., Li, Y., Eilert, S., & Tomasula, P. M. (2023). Macrophage-Immunomodulatory Actions of Bovine Whey Protein Isolate, Glycomacropeptide, and Their In Vitro and In Vivo Digests. *Foods*, 12(13), 2577. https://doi.org/10.3390/foods12132577

Phillips, S. M., Tipton, K. D., Ferrando, A. A., & Wolfe, R. R. (1999). Resistance training reduces the acute exercise-induced increase in muscle protein turnover. *American Journal of Physiology*, *276*(1 Pt 1), E118–E124. https://pubmed.ncbi.nlm.nih.gov/9886957/

Pinckaers, P. J. M., Kouw, I. W. K., Gorissen, S. H. M., Wouters, M., & van Loon, L. J. C. (2022). The Muscle Protein Synthetic Response to the Ingestion of a Plant-Derived Protein Blend Does Not Differ from an Equivalent Amount of Milk Protein in Healthy Young Males. *The Journal of Nutrition*, 152(12), 2736–2744. https://doi.org/10.1016/j.tjnut.2022.08.006

Potential Prebiotic Properties of Whey Protein and Glycomacropeptide in Gut Microbiome. (2024). *Food Science of Animal Resources*, 44(2), 263-272. https://doi.org/10.5851/kosfa.2024.e19

Rackerby, B., Le, H. N. M., Haymowicz, A., Kincaid, C., & Kim, Y. (2024). Potential Prebiotic Properties of Whey Protein and Glycomacropeptide in Gut Microbiome. *Food Science of Animal Resources*, 44(2), 263-272. https://doi.org/10.5851/kosfa.2024.e19

Rohr, M. W., Narasimhulu, C. A., Rudeski-Rohr, T. A., & Parthasarathy, S. (2020). Negative Effects of a High-Fat Diet on Intestinal Permeability: A Review. In Advances in Nutrition (Vol. 11, Issue 1, pp. 77–91). Oxford University Press. https://doi.org/10.1093/advances/nmz061

Shukla, N., Tripathi, A. K., Tiwari, A., et al. (2024). Decoding A1 and A2 milk: A thorough exploration. *International Journal of Agriculture Extension and Social Development*, *9*(1), 12–21.

Song, C.-H., Kim, N., Choi, Y., et al. (2025). Beneficial effect of consuming milk containing only A2 beta-casein on gut microbiota: A single-center, randomized, double-blind, cross-over study. *PLOS ONE*, *20*(5), e0323016. https://doi.org/10.1371/journal.pone.0323016

Tang, J. E., Moore, D. R., Kujbida, G. W., Tarnopolsky, M. A., & Phillips, S. M. (2009). Ingestion of whey hydrolysate, casein, or soy protein isolate: Effects on mixed muscle protein synthesis at rest and following resistance exercise in young men. *Journal of Applied Physiology*, *107*(3), 987–992. https://doi.org/10.1152/japplphysiol.00076.2009

Tenenbaum, M., Dugardin, C., Moro, J., Auger, J., Baniel, A., Boulier, A., Ravallec, R., & Cudennec, B. (2023). In vitro comparison of whey protein isolate and hydrolysate for their effect on glucose homeostasis markers. Food and Function, 14(9), 4173–4182. https://doi.org/10.1039/d3fo00467h

West, D. W. D., Sawan, S. A., Mazzulla, M., Williamson, E., & Moore, D. R. (2017). Whey protein supplementation enhances whole body protein metabolism and performance recovery after resistance exercise: A double-blind crossover study. Nutrients, 9(7). https://doi.org/10.3390/nu9070735

Zak-Gołąb, A., Kocełak, P., Aptekorz, M., Zientara, M., Juszczyk, Ł., Martirosian, G., Chudek, J., & Olszanecka-Glinianowicz, M. (2013). Gut microbiota, microinflammation, metabolic profile, and zonulin concentration in obese and normal weight subjects. International Journal of Endocrinology, 2013. https://doi.org/10.1155/2013/674106

Author Information

Dr. Eugene Capitano, DC, MSc (Neuroscience & Psychology of Mental Health, King's College London), Research interests: gut-brain axis, functional nutrition, and translational microbiome science.